Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

By J. Masferrer, K. Leahy, A. Koki, B. Zweifel, S. Settle, B. M. Woerner, Dorothy A. Edwards, A. G. Flickinger, R. Moore, K. Seibert. Cancer Research, 2000

1,381 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/88671f722e98d8a8621521d7efe8f7e52aa92de7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Phenotype and Genotype of Pancreatic Cancer Cell Lines (2010, background): “One mechanism through which COX-2 promotes angiogenesis is by converting arachidonic acid into bioactive molecules, such as prostaglandin E2 (PGE2), which act as activating factors in angiogenesis.(61) Furthermore, selective COX-2 inhibitors potentiate the growth inhibitory effects of chemotherapeut”
Selective COX-1 inhibition: A therapeutic target to be reconsidered. (2010, background): “COX-1 inhibitor SC-560, as well as non-selective COX inhibitor ibuprofen, significantly blocked PGE2 and VEGF release, indicating that both enzymes participate in PGE2 production, probably to a different extent.”
The anti-angiogenic basis of metronomic chemotherapy (2004, background): “Celecoxib was selected for inclusion in the trial because of its commercial availability, ease of administration, excellent side-effect profile and putative anti-angiogenic effect”
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. (2007, background): “The antitumor effects of these agents have been attributed to various mechanisms, such as enhancing angiogenesis (34) and inducing tumor cell apoptosis (35).”
The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. (2005, background): “o-3 LCPUFAs may also show merit as complementary therapies with COX (Masferrer et al., 2000) inhibitors and LOX metabolites (Hong et al.”